Search

376 Result(s)
Sort by

Who are we?

Who are we?

Started in 1885 by Albert Boehringer, this independent family-owned company has grown into a top contributor in Human Pharma and Animal Health.
Our people

Our people

Ambition. Passion. Integrity. Commitment. Empathy. Individuality. We expect these qualities at all levels.
commitments to sustainable development

commitments to sustainable development

On One Health Day, Boehringer Ingelheim shares an update on its strategic approach to sustainability for employees, partners and wider communities
university-of-medical-excellence-harvard

university-of-medical-excellence-harvard

A program designed by Harvard Medical School Executive Education with the goal of accelerating clinical development and medical affairs
Kicking off 2024 with five new R&D partnerships

Kicking off 2024 with five new R&D partnerships

We are kicking off 2024 with five new R&D partnerships to further enable and accelerate the company’s commitment to transform the lives of patients world-wide.
Growing with us

Growing with us

We recognize the benefits of learning and have created an environment where life-long learning and personal growth are encouraged for all employees.
Our Expectations

Our Expectations

We expect adherence to exemplary ethical and professional conduct both within the company and from our business partners.
Pascal Haubert

Pascal Haubert

Three months into an internship with us, Pascal Haubert talks about responsibility, learning, and mutual support.
founding-member-of-QUTAC

founding-member-of-QUTAC

Together, the members of this newly founded consortium want to explore industrial applications for quantum computing
China pioneers biosecurity report against ASF

China pioneers biosecurity report against ASF

Boehringer Ingelheim compiles data from 1,000 swine farms into the first market report on biosecurity. Document sheds light on livestock management and contributes to the fight against African swine fever.
empa-reg-outcome-recurrent-events

empa-reg-outcome-recurrent-events

EMPA-REG OUTCOME® analysis: Empagliflozin reduced risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and CV disease